Jeremy Bender, Ph.D., M.B.A. has served as our Chief Executive Officer, President and a member of our board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, a pharmaceutical company, from March 2018 to September 2020.
Prior to that, he was Chief Operating Officer of Tizona Therapeutics from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, he was Vice President of Corporate Development at Allos Therapeutics, a biotechnology company focused on cancer treatments, from January 2006 to September 2012.
Dr. Bender also sits on the board of Mereo BioPharma as an independent board member. He started his career in the life sciences practice at Boston Consulting Group, a management consulting company.
Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.
What is Jeremy Bender's net worth?
The estimated net worth of Jeremy Bender is at least $1.48 million as of November 17th, 2025. Mr. Bender owns 177,165 shares of Day One Biopharmaceuticals stock worth more than $1,477,556 as of December 4th. This net worth approximation does not reflect any other investments that Mr. Bender may own. Additionally, Mr. Bender receives a salary of $900,000.00 as CEO at Day One Biopharmaceuticals. Learn More about Jeremy Bender's net worth.
How old is Jeremy Bender?
What is Jeremy Bender's salary?
How do I contact Jeremy Bender?
Has Jeremy Bender been buying or selling shares of Day One Biopharmaceuticals?
In the last ninety days, Jeremy Bender has sold $141,615.54 in shares of Day One Biopharmaceuticals stock. Most recently, Jeremy Bender sold 15,894 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $8.91, for a transaction totalling $141,615.54. Following the completion of the sale, the chief executive officer now directly owns 177,165 shares of the company's stock, valued at $1,578,540.15. Learn More on Jeremy Bender's trading history.
Who are Day One Biopharmaceuticals' active insiders?
Are insiders buying or selling shares of Day One Biopharmaceuticals?
During the last twelve months, insiders at the sold shares 16 times. They sold a total of 134,085 shares worth more than $1,259,570.00. The most recent insider tranaction occured on November, 17th when insider Adam Dubow sold 4,319 shares worth more than $38,482.29. Insiders at Day One Biopharmaceuticals own 6.2% of the company.
Learn More about insider trades at Day One Biopharmaceuticals. Information on this page was last updated on 11/17/2025.
